Research Article
Biglycan Overexpression Predicts Poor Prognosis of Gastric Cancer
Xin-zhou Huang1,3,#, Hui Chen1,2,#, Wen-ming Song9,#, Ying-ying Wang4,5, Mei–yuan Zhou8, Hui-chuan Zhao8, Na Li6, Bing Zheng1,2, Quan Gong1,2,*, Ke-bin Liu3,*, Hong-wu Xin4,7,*
1Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China; 2Clinical Molecular Immunology Center, School of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China; 3Department of Orthopedics, Affiliated the First Hospital Yangtze University, Jingzhou, Hubei Province 434023, PR China; 4Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China; 5Gynaecology Research Unit, Hannover Medical School, Hannover, D30625, Germany; 6Department of Oncology, Affiliated the First Hospital Yangtze University, Jingzhou, Hubei Province 434023, PR China; 7Department of Biochemistry and Molecular Biology, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China; 8Department of Pathology, Affiliated the First Hospital Yangtze University, Hubei 434000, China; 9Department of Neurology, Lianjiang people’s Hospital, Lianjiang, Guangdong Province 524400, PR China.
#, These authors contributed equally to this work.
*, Correspondence
Quan Gong, Ph.D., Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China. Email: [email protected].
Ke-bin Liu, M.M., Department of Orthopedics, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei Province 434023, PR China. Email: [email protected].
Hong-wu Xin, Ph.D., Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Faculty of Medicine, Yangtze University, Jingzhou, Hubei Province 434023, PR China. Email: [email protected].
Received: July 23, 2023; Accepted: May 1, 2024; Published online: September 5, 2024.
Cite this paper: Xin-zhou Huang, Hui Chen, Wen-ming Song, Ying-ying Wang, Mei-yuan Zhou, Hui-chuan Zhao, Na Li, Bing Zheng, Quan Gong, Ke-bin Liu, Hong-wu Xin. (2024) Biglycan Overexpression Predicts Poor Prognosis of Gastric Cancer. Global Journal of Medicine, 5(2):38-53. http://naturescholars.com/gjm.050203. https://doi.org/10.46633/gjm.050203.
Copyright© 2024 by Scholars Publishing, LLC.
Abstract
Biglycan (BGN) encodes an extracellular matrix (ECM) proteoglycan. However, the potential diagnostic and prognostic value of BGN in gastric cancer (GC) have not yet been reported. In this analysis, BGN expression in GC was evaluated across the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and Oncomine databases, and verified using immunohistochemistry (IHC). In this analysis, the expression of BGN in gastric cancer was evaluated by bioinformatics analysis and validated by immunohistochemistry (IHC). The relationship between BGN expression and clinicopathological parameters was assessed by chi-square test and logistic regression. We analyzed the prognostic value of BGN. Then, Gene set enrichment analysis (GSEA) was used to screen the signaling pathways involved in high BGN expression datasets in GC. Finally, CIBERSORT was used to evaluate the infiltration of immune cells in GC tissues, and the correlation between BGN and infiltrating immune cells was analyzed. Then the signaling pathways involved in the BGN highly expressed data set in GC were screened. Finally, the infiltration of immune cells in GC tissues was evaluated. The results showed that the mRNA levels of BGN were significantly up-regulated in GC compared with normal tissues (all p< 0.001). The Kaplan-Meier plotter online database suggested that patients with high BGN expression had a poor prognosis (P=1.3e-10). In addition, using gene sets analysis, we found that pathways of bladder cancer, Wnt-signaling, TGF-beta signaling, and ECM-receptor interaction were differentially activated in high-expression BGN tissues. In addition, we found that multiple signaling pathways are activated to varying degrees in the highly expressed BGN tissues. Furthermore, CIBERSORT analysis for the proportion of tumor initiating cells (TICs) revealed that macrophages M2 was positively correlated with BGN expression. We provided the first evidence that BGN overexpression predicts poor prognosis of GC and BGN is a potential biomarker for GC prognosis. The finding may have significant implication for the diagnosis, prognosis and treatment of GC.
Key words: Biglycan; Gastric cancer; TCGA; GSEA; CIBERSORT; Macrophages M2.